MedTrace Logo

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

NCT01268280 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-09-24

No results posted yet for this study

Summary

The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).

Conditions

Interventions

DRUG

Placebo

Matching placebo in capsules administered as a single oral dose.

DRUG

250 mg CK-2017357

250 mg CK-2017357 in capsules administered as a single oral dose.

DRUG

500 mg CK-2017357

500 mg CK-2017357 in capsules administered as a single oral dose.

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Cytokinetics

    lead INDUSTRY

Principal Investigators

  • Andrew Wolff, MD, FACC · Cytokinetics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01268280 on ClinicalTrials.gov